FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182086608> ?p ?o ?g. }

• W3182086608 endingPage "e002267" @default.
• W3182086608 startingPage "e002267" @default.
• W3182086608 abstract "Children with recurrent and/or metastatic osteosarcoma (OS), neuroblastoma (NB) and glioblastoma multiforme (GBM) have a dismal event-free survival (<25%). The majority of these solid tumors highly express GD2. Dinutuximab, an anti-GD2 monoclonal antibody, significantly improved event-free survival in children with GD2+ NB post autologous stem cell transplantation and enhanced natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity. Thus, approaches to increase NK cell number and activity, improve persistence and trafficking, and enhance tumor targeting may further improve the clinical benefit of dinutuximab. N-803 is a superagonist of an interleukin-15 (IL-15) variant bound to an IL-15 receptor alpha Su-Fc fusion with enhanced biological activity.The anti-tumor combinatorial effects of N-803, dinutuximab and ex vivo expanded peripheral blood NK cells (exPBNK) were performed in vitro using cytoxicity assays against GD2+ OS, NB and GBM cells. Perforin and interferon (IFN)-γ levels were measured by ELISA assays. Multiple cytokines/chemokines/growth factors released were measured by multiplex assays. Human OS, GBM or NB xenografted NOD/SCID/IL2rγnull (NSG) mice were used to investigate the anti-tumor combinatorial effects in vivo.N-803 increased the viability and proliferation of exPBNK. The increased viability and proliferation are associated with increased phosphorylation of Stat3, Stat5, AKT, p38MAPK and the expression of NK activating receptors. The combination of dinutuximab and N-803 significantly enhanced in vitro cytotoxicity of exPBNK with enhanced perforin and IFN-γ release against OS, GBM and NB. The combination of exPBNK+N-803+dinutuximab significantly reduced the secretion of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), platelet-derived growth factor-BB (PDGF-BB), and stem cell growth factor beta (SCGF-β) from OS or GBM tumor cells. Furthermore, OS or GBM significantly inhibited the secretion of regulated on activation, normal T cell expressed and presumably secreted (RANTES) and stromal cell-derived factor-1 alpha (SDF-1α) from exPBNK cells (p<0.001) but significantly enhanced monokine induced by gamma interferon (MIG) secretion from exPBNK cells (p<0.001). N-803 combined with dinutuximab and exPBNK cells significantly extended the survival of OS, GBM or NB xenografted NSG mice.Our results provide the rationale for the development of a clinical trial of N-803 in combination with dinutuximab and ex vivo exPBNK cells in patients with recurrent or metastatic GD2+ solid tumors." @default.
• W3182086608 created "2021-07-19" @default.
• W3182086608 creator A5001697191 @default.
• W3182086608 creator A5012115728 @default.
• W3182086608 creator A5017266140 @default.
• W3182086608 creator A5019752519 @default.
• W3182086608 creator A5028012551 @default.
• W3182086608 creator A5046152112 @default.
• W3182086608 creator A5078245032 @default.
• W3182086608 creator A5087962211 @default.
• W3182086608 date "2021-07-01" @default.
• W3182086608 modified "2023-09-26" @default.
• W3182086608 title "Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2⁺pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice" @default.
• W3182086608 cites W1484816825 @default.
• W3182086608 cites W1601789294 @default.
• W3182086608 cites W1936300843 @default.
• W3182086608 cites W1972178991 @default.
• W3182086608 cites W1973745263 @default.
• W3182086608 cites W1977408485 @default.
• W3182086608 cites W1980487981 @default.
• W3182086608 cites W1988382766 @default.
• W3182086608 cites W1990428948 @default.
• W3182086608 cites W2000166702 @default.
• W3182086608 cites W2002595222 @default.
• W3182086608 cites W2020646453 @default.
• W3182086608 cites W2027053879 @default.
• W3182086608 cites W2030068760 @default.
• W3182086608 cites W2031825024 @default.
• W3182086608 cites W2033037904 @default.
• W3182086608 cites W2033296826 @default.
• W3182086608 cites W2041680367 @default.
• W3182086608 cites W2052801683 @default.
• W3182086608 cites W2064873657 @default.
• W3182086608 cites W2081465946 @default.
• W3182086608 cites W2091675007 @default.
• W3182086608 cites W2092058648 @default.
• W3182086608 cites W2093555412 @default.
• W3182086608 cites W2094688765 @default.
• W3182086608 cites W2104607769 @default.
• W3182086608 cites W2112633838 @default.
• W3182086608 cites W2130465135 @default.
• W3182086608 cites W2141632229 @default.
• W3182086608 cites W2146778105 @default.
• W3182086608 cites W2175045656 @default.
• W3182086608 cites W2289343847 @default.
• W3182086608 cites W2346520135 @default.
• W3182086608 cites W2598950561 @default.
• W3182086608 cites W2652571037 @default.
• W3182086608 cites W2736567681 @default.
• W3182086608 cites W2759314369 @default.
• W3182086608 cites W2764179479 @default.
• W3182086608 cites W2766369880 @default.
• W3182086608 cites W2788914092 @default.
• W3182086608 cites W2791218690 @default.
• W3182086608 cites W2794892435 @default.
• W3182086608 cites W2889001017 @default.
• W3182086608 cites W2889295234 @default.
• W3182086608 cites W2889489530 @default.
• W3182086608 cites W2909586431 @default.
• W3182086608 cites W2913289941 @default.
• W3182086608 cites W2914155390 @default.
• W3182086608 cites W3002842519 @default.
• W3182086608 cites W3013135919 @default.
• W3182086608 doi "https://doi.org/10.1136/jitc-2020-002267" @default.
• W3182086608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8268924" @default.
• W3182086608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34244307" @default.
• W3182086608 hasPublicationYear "2021" @default.
• W3182086608 type Work @default.
• W3182086608 sameAs 3182086608 @default.
• W3182086608 citedByCount "11" @default.
• W3182086608 countsByYear W31820866082021 @default.
• W3182086608 countsByYear W31820866082022 @default.
• W3182086608 countsByYear W31820866082023 @default.
• W3182086608 crossrefType "journal-article" @default.
• W3182086608 hasAuthorship W3182086608A5001697191 @default.
• W3182086608 hasAuthorship W3182086608A5012115728 @default.
• W3182086608 hasAuthorship W3182086608A5017266140 @default.
• W3182086608 hasAuthorship W3182086608A5019752519 @default.
• W3182086608 hasAuthorship W3182086608A5028012551 @default.
• W3182086608 hasAuthorship W3182086608A5046152112 @default.
• W3182086608 hasAuthorship W3182086608A5078245032 @default.
• W3182086608 hasAuthorship W3182086608A5087962211 @default.
• W3182086608 hasBestOaLocation W31820866081 @default.
• W3182086608 hasConcept C109316439 @default.
• W3182086608 hasConcept C150903083 @default.
• W3182086608 hasConcept C185592680 @default.
• W3182086608 hasConcept C202751555 @default.
• W3182086608 hasConcept C203014093 @default.
• W3182086608 hasConcept C207001950 @default.
• W3182086608 hasConcept C2776062744 @default.
• W3182086608 hasConcept C2777701055 @default.
• W3182086608 hasConcept C40677261 @default.
• W3182086608 hasConcept C502942594 @default.
• W3182086608 hasConcept C55493867 @default.
• W3182086608 hasConcept C86803240 @default.
• W3182086608 hasConcept C8891405 @default.
• W3182086608 hasConceptScore W3182086608C109316439 @default.
• W3182086608 hasConceptScore W3182086608C150903083 @default.

• next